Special Issue "Mitochondrial Dysfunction in Cardiovascular Disease"
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 27400
Mitochondria lie at the crossroad of cellular metabolic and signaling pathways. Beyond energy production, mitochondria generate key metabolites and biochemical signals crucial for maintaining cell function and health. Studies have shown that functional and structural defects in these vital organelles are implicated in the pathophysiology of cardiovascular disease. Not surprisingly, mitochondrial function has emerged as a promising therapeutic target for cardiovascular disease treatment. However, despite striking outcomes in preclinical studies, the translation of mitochondrial-targeted therapies to the clinic has not been successful to date, suggesting that there is still a lack of an integrative understanding of the mechanisms linking mitochondrial dysfunction and cardiovascular disease.
Cells is planning to publish a Special Issue in Fall 2022 titled “Mitochondrial Dysfunction in Cardiovascular Disease” that will solicit original research articles, short communications, and brief reviews highlighting new and exciting findings in the area of mitochondrial dysfunction in cardiovascular disease. We invite submissions that focus on the mechanisms linking mitochondrial dysfunction and cardiovascular disease and mitochondrial-targeted therapies, including but not limited to mitochondrial-derived signals for cardiac protection; arrhythmias or sudden death; non-coding RNAs; and epigenetic, genetic, and computational approaches for the identification and validation of novel mitochondrial therapeutic targets. Each submitted manuscript will go through a rigorous peer-review process. Submitted manuscripts must not have been published previously nor be under consideration at other journals.
Dr. Lufang Zhou
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cardiovascular disease
- mitochondrial dysfunction
- mitochondrial targeted therapy
- non-coding RNAs
- computational model